Related Experiment Video

Updated: Feb 23, 2026

Surgical Treatment of an Endolymphatic Sac Tumor
04:34

Surgical Treatment of an Endolymphatic Sac Tumor

Published on: May 26, 2023

1.7K

Cyclical vomiting syndrome secondary to a Chiari I malformation-a case report

William L White1,2, Veejay Bagga3, David I Campbell4

  • 1The Medical School, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK. wlwhite1@sheffield.ac.uk.

Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery
|September 13, 2017
PubMed

Insights

Cyclical vomiting syndrome in children can be associated with Chiari malformation type I. Craniocervical decompression surgery provided symptomatic relief for a pediatric patient with both conditions.

Area of Science:

  • Pediatric Neurology
  • Neurosurgery
  • Gastroenterology

Background:

  • Cyclical vomiting syndrome (CVS) is a disorder causing recurrent, severe vomiting episodes.
  • The co-occurrence of CVS and Chiari malformation type I in pediatric patients is not well-documented in medical literature.

Observation:

  • A 12-year-old child presented with symptoms consistent with cyclical vomiting syndrome.
  • Diagnostic imaging revealed the presence of Chiari malformation type I in the same patient.

Findings:

  • The pediatric patient was diagnosed with both cyclical vomiting syndrome and Chiari malformation type I.
  • Symptomatic improvement was observed following craniocervical decompression surgery.

Implications:

  • This case highlights a potential link between CVS and Chiari malformation type I in children.
  • Craniocervical decompression may be a viable treatment option for pediatric patients with coexisting CVS and Chiari malformation type I.
  • Further research is warranted to explore the pathophysiology and management of this combined condition.
Abstract

Keywords:
Chiari malformation type ICraniocervical decompressionCyclical vomiting syndrome

More Related Videos

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

1.3K

Related Concept Videos

Pathophysiology of Vomiting01:22

Pathophysiology of Vomiting

Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...
3.4K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
658
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
726
Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
790
Esophageal Strictures-II: Clinical Features and Management01:26

Esophageal Strictures-II: Clinical Features and Management

Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
736
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
678